CClinicalTrials.gg
CompletedNCT06654687Updated May 21, 2025

Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia

An interventional study of Transthoracic Echocardiography and Ringer lactate 1000 ml in Pregnancy, Cesarean Delivery and Spinal Anesthesia Induced Hypotension, sponsored by Sameh Fathy. Completed at 1 site in Egypt. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Sameh Fathy · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Randomized
Sex
Female
01

Study summary

Transthoracic echocardiography (TTE) has been introduced in anesthesia and intensive care practice to assess the volume status and predict fluid responsiveness, with a few studies performed on pregnant women (5).

In this study, we aim to evaluate the effect of intravenous administration of albumin as a colloid preload on the maternal stroke volume (SV) and cardiac output (CO) versus crystalloid coload. We used TTE to measure the changes in SV, and CO at baseline and at subsequent time points after spinal anesthesia.

Read the detailed description

This prospective randomized controlled, double-blind study will be conducted at the obstetrics and gynecology operation room, at Qassim University Medical City.

Written informed consent will be obtained from eligible subjects on the day of the surgery. The study subjects will be randomized using the R software, version 3.5.2 (R Core Team, 2018; R Foundation for Statistical Computing, Vienna, Austria). Subjects will randomly be assigned to 2 equal groups (combined and crystalloid coload) using the permuted block randomization method with randomly selected block sizes of 4 and 6. The group allocation codes will be hidden in sequentially numbered, opaque, sealed envelopes that will be opened only after assessing the eligibility and obtaining the consent from the subjects. The study subjects and the outcome assessors will be blinded to the study group.

Spinal anesthesia will be conducted will be assessed respectively by an anesthesiologist not involved in the study.

All transthoracic cardiography images will be obtained by the second investigator who have the experience of accomplishing > 500 cases before starting the study using the technique and guidelines reported in American Society of Echocardiography . During obtaining the images intraoperatively, the investigator will be separated from the surgical field by a sterile drape, and the ultrasound probe will be covered with a sterile cover.

The study subjects will enter the operating room, lying supine on the operating table with slight left lateral position by tilting the operating table to the left. Standard monitors will be attached to all patients (noninvasive blood pressure, pulse oximeter, and electrocardiography). Basal systolic blood pressure and heart rate will be recorded after a period of rest, the average of 3 readings, 2 minutes apart will be recorded. Basal transthoracic cardiography images will be obtained.

Two 18-gauge intravenous cannula will be inserted in two large veins of the right forearm, one for IV fluids, and the other for phenylephrine infusion. In the combination group, patients will receive 250 mL of human albumin 5% (Human Albumin 50 gm/L, BAXTER, Austria) immediately before induction of spinal anesthesia (SA), over 10 minutes using an infusion pump (Fresenius Kabi Agilia Volumat MC Infusion Pump, Germany), and 750 mL of Ringer's lactate solution, to be started during the intrathecal injection of the local anesthetic, and infused over 15 minutes. In the crystalloid coload group, patients will receive 1000 mL of Ringer's lactate solution, to be started during the intrathecal injection of the local anesthetic, and infused over 15 minutes. In both groups, phenylephrine infusion will be given prophylactically, and will be started during the intrathecal injection of the local anesthetic at a dose ranging from 25-50 mcg/minute to maintain the SBP within 20 % of the basal readings. After administering the study solutions, Ringer's lactate will be attached to the IV cannula and will be administered at a rate of 1 mL/min; no other fluids will be administered until clamping of the umbilical cord (end of the study period).

In the sitting position, spinal anesthesia will be conducted by intrathecal injection of hyperbaric bupivacaine 12.5 mg 0.5% and fentanyl 15 microgram, using 27-gauge pencil point spinal needle at L3-L4 intervertebral space.

Surgery will be started after reaching at least an upper sensory level of T4; below this level, spinal anesthesia will be considered failed and patients will be excluded from the study.

SV and CO will be measured at 5 time points (basal readings, 1 minute after SA, 5 minutes after SA, immediately after delivery of the baby and clamping the cord, and 1 hour after the end of the study). SBP and HR will be recorded ever minute till the delivery of the baby, then every 3 minutes till the end of the surgery.

02

Conditions studied

  • Pregnancy
  • Cesarean Delivery
  • Spinal Anesthesia Induced Hypotension
  • Cardiac Output Measurement
  • Volume Status

Browse trials for

Keywords

  • Cardiac output- Transthoracic ECHO - Colloids - Crystalloids - Cesarean delivery - Spinal anesthesia
03

In context

Hypotension

1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.

This study's enrollment of 162 is above the median of 80 across 675 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Sameh Fathy is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • American Society of Anesthesiologists physical status II parturients with full term singleton pregnancies scheduled for elective cesarean delivery under spinal anesthesia.

Exclusion criteria

Exclusion Criteria:

  • Height \<150 cm, weight \<55 kg, and body mass index ≥40 kg/m2.
  • Women presenting in labor or having any contraindication to spinal anesthesia (patient refusal, increased intracranial pressure, coagulation disorders, or local skin infection).
  • Chronic or pregnancy-induced hypertension; baseline systolic blood pressure >140 mm Hg.
  • Hemoglobin \<10 g/dL.
  • Diabetes mellitus.
  • Cardiovascular, cerebrovascular, or renal disease.
  • Polyhydramnios or fetal abnormalities.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Active comparator
    Crystalloid group

    Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output. Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.

    Device: Transthoracic Echocardiography · Drug: Ringer lactate 1000 ml

  • Active comparator
    Combination group

    Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output. Patients will receive 250 mL of human albumin 5% over 10 minutes and 750 mL of Ringer's lactate solution over 15 minutes.

    Device: Transthoracic Echocardiography · Drug: Albumin · Drug: Ringer lactate 750 ml

Interventions

  • DeviceTransthoracic Echocardiography

    Transthoracic Echocardiography will be used to measure the changes in stroke volume and cardiac output.

  • DrugRinger lactate 1000 ml

    Patients will receive 1000 mL of Ringer's lactate solution over 15 minutes.

  • DrugAlbumin

    Patients will receive 250 mL of human albumin 5% over 10 minutes

  • DrugRinger lactate 750 ml

    Patients will receive 750 mL of Ringer's lactate solution over 15 minutes.

06

What researchers measure

Primary outcomes

  1. Changes in Cardiac Output

    The changes in Cardiac Output are measured relative to baseline immediately after delivery

    Time frame: Immediately after delivery of baby

Secondary outcomes

  1. Changes in stroke volume

    The changes in stroke volume are measured compared to the baseline immediately after delivery

    Time frame: Immediately after delivery of baby

  2. Total phenylephrine dose (mg)

    Time frame: Until delivery of baby

  3. Total ephedrine dose (mg)

    Time frame: Until delivery of the baby

  4. Total glycopyrrolate dose (mg)

    Time frame: Until delivery of the baby

  5. Incidence of hypotension

    Decrease in SBP \> 20% of the basal reading

    Time frame: Until end of surgery

  6. Incidence of bradycardia

    Heart rate \< 50 beats/minute

    Time frame: Until end of surgery

  7. Incidence of nausea and/or vomiting

    Time frame: Until end of surgery

  8. Measurement of APGAR score

    APGAR score includes appearance, pulse, grimace, activity and respiration

    Time frame: 1 minute and 5 minutes after delivery of the baby

  9. Measurement of Urine output (ml)

    Time frame: 1 hour after delivery of the baby

07

Study locations

1 site
  • Mansoura University
    Mansoura, Egypt
08

References and documents

Publications

  • Porter TR, Shillcutt SK, Adams MS, Desjardins G, Glas KE, Olson JJ, Troughton RW. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015 Jan;28(1):40-56. doi: 10.1016/j.echo.2014.09.009. No abstract available. PubMed 25559474 ↗
  • Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010. No abstract available. PubMed 20620859 ↗
  • McDonald S, Fernando R, Ashpole K, Columb M. Maternal cardiac output changes after crystalloid or colloid coload following spinal anesthesia for elective cesarean delivery: a randomized controlled trial. Anesth Analg. 2011 Oct;113(4):803-10. doi: 10.1213/ANE.0b013e31822c0f08. Epub 2011 Sep 2. PubMed 21890886 ↗
  • Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb;124(2):270-300. doi: 10.1097/ALN.0000000000000935. No abstract available. PubMed 26580836 ↗
  • Mercier FJ. Fluid loading for cesarean delivery under spinal anesthesia: have we studied all the options? Anesth Analg. 2011 Oct;113(4):677-80. doi: 10.1213/ANE.0b013e3182245af4. No abstract available. PubMed 21948275 ↗
  • Loubert C. Fluid and vasopressor management for Cesarean delivery under spinal anesthesia: continuing professional development. Can J Anaesth. 2012 Jun;59(6):604-19. doi: 10.1007/s12630-012-9705-9. Epub 2012 Apr 24. English, French. PubMed 22528166 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06654687
Lead sponsor
Sameh Fathy
Responsible party
Sameh Fathy (Assistant Professor of Anesthesia and ICU - Faculty of Medicine - Mansoura University, Mansoura University) — Sponsor-investigator
First posted
Oct 23, 2024
Start date
Oct 27, 2024
Primary completion
Feb 15, 2025
Completion
Mar 1, 2025
Last update
May 21, 2025

Study contacts

MOHAMED TOLBA ELMORSY, MD
principal investigator · Lecturer of Anesthesia and ICU - Faculty of Medicine - Mansoura University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion